Skip to content

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Characterizing travel burden in oncology clinical trials: A single-institution analysis.

129 Background: Geographic access remains a significant barrier to enrollment of patients (pts) in oncology clinical trials. Previous studies have found that travel burden may disproportionately affect vulnerable racial and ethnic groups and contribute to inequities in trial enrollment (1). This study evaluated...

N. Duggirala, S. J. Park, Andy Han et al. · 0 citations
Open access Sep 2026

Lessons from Cohort Studies of Targetable Metabolic Deficiencies in Lung Cancer

Summary MTAP loss is among the most common potentially targetable driver mutations in NSCLC. Early phase clinical trials are ongoing. Although susceptible to various biases, retrospective studies may serve as a historical control to interpret single arm studies. Combination therapies and novel biomarkers may also impro...

Daniel Li, E. Garon · 0 citations
Open access Oct 2026

A CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trial

Immune checkpoint inhibitors (ICIs) have transformed treatment for non-small cell lung cancer (NSCLC), but resistance to these therapies is common. We report here results from a phase I trial combining intratumoral injection of a CCL21-expressing dendritic cell (CCL21-DC) vaccine with pembrolizumab in patients with...

M. Oh, A. Lisberg, C. Dumitras et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.